Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Mannaerts

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Human Reproduction (Oxford, England)|June 30, 2000
Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study GroupG Borm, B Mannaerts
Human Reproduction (Oxford, England)|September 1, 2000
Embryo implantation and GnRH antagonists: GnRH antagonists do not activate the GnRH receptorB Mannaerts, K Gordon
Human Reproduction (Oxford, England)|September 1, 2000
Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communicationJ Itskovitz-Eldor, S Kol, B Mannaerts
Human Reproduction (Oxford, England)|February 3, 2000
Local tolerance, pharmacokinetics, and dynamics of ganirelix (Orgalutran) administration by Medi-Jector compared to conventional needle injectionsJ Oberyé, B Mannaerts, J Huisman, et al.
Human Reproduction (Oxford, England)|September 29, 2011
Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pre-treatmentA Nyboe Andersen, H Witjes, K Gordon, et al.
Fertility and Sterility|January 1, 1994
Circulating bioactive and immunoreactive recombinant human follicle stimulating hormone (Org 32489) after administration to gonadotropin-deficient subjectsT Matikainen, R De Leeuw, B Mannaerts, et al.
Fertility and Sterility|April 1, 1993
Induction of follicular growth using recombinant human follicle-stimulating hormone in two volunteer women with hypogonadotropic hypogonadismZ Shoham, B Mannaerts, V Insler, et al.
Biology of Reproduction|July 1, 1994
Folliculogenesis in hypophysectomized rats after treatment with recombinant human follicle-stimulating hormoneB Mannaerts, J Uilenbroek, P Schot, et al.
Human Reproduction (Oxford, England)|April 29, 1998
First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462)J Itskovitz-Eldor, S Kol, B Mannaerts, et al.
Human Reproduction (Oxford, England)|July 28, 2001
Perinatal outcome of pregnancy after GnRH antagonist (ganirelix) treatment during ovarian stimulation for conventional IVF or ICSI: a preliminary reportF Olivennes, B Mannaerts, M Struijs, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Human Reproduction (Oxford, England)|June 30, 2000
Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study GroupG Borm, B Mannaerts
Human Reproduction (Oxford, England)|September 1, 2000
Embryo implantation and GnRH antagonists: GnRH antagonists do not activate the GnRH receptorB Mannaerts, K Gordon
Human Reproduction (Oxford, England)|September 1, 2000
Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communicationJ Itskovitz-Eldor, S Kol, B Mannaerts
Human Reproduction (Oxford, England)|February 3, 2000
Local tolerance, pharmacokinetics, and dynamics of ganirelix (Orgalutran) administration by Medi-Jector compared to conventional needle injectionsJ Oberyé, B Mannaerts, J Huisman, et al.
Human Reproduction (Oxford, England)|September 29, 2011
Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pre-treatmentA Nyboe Andersen, H Witjes, K Gordon, et al.
Fertility and Sterility|January 1, 1994
Circulating bioactive and immunoreactive recombinant human follicle stimulating hormone (Org 32489) after administration to gonadotropin-deficient subjectsT Matikainen, R De Leeuw, B Mannaerts, et al.
Fertility and Sterility|April 1, 1993
Induction of follicular growth using recombinant human follicle-stimulating hormone in two volunteer women with hypogonadotropic hypogonadismZ Shoham, B Mannaerts, V Insler, et al.
Biology of Reproduction|July 1, 1994
Folliculogenesis in hypophysectomized rats after treatment with recombinant human follicle-stimulating hormoneB Mannaerts, J Uilenbroek, P Schot, et al.
Human Reproduction (Oxford, England)|April 29, 1998
First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462)J Itskovitz-Eldor, S Kol, B Mannaerts, et al.
Human Reproduction (Oxford, England)|July 28, 2001
Perinatal outcome of pregnancy after GnRH antagonist (ganirelix) treatment during ovarian stimulation for conventional IVF or ICSI: a preliminary reportF Olivennes, B Mannaerts, M Struijs, et al.
Pageof 3